Page last updated: 2024-08-05 11:42:39

rotenones

Members of the class of rotenoid which consists of a 6a,12a-dihydrochromeno[3,4-b]chromen-12(6H)-one skeleton and its substituted products.

ChEBI ID: 72581

Members (6)

MemberDefinitionRole
(6aS,12aS)-9-hydroxy-2,3-dimethoxy-8-(3-methylbut-2-enyl)-6a,12a-dihydro-6H-[1]benzopyrano[3,4-b][1]benzopyran-12-one(6aS,12aS)-9-hydroxy-2,3-dimethoxy-8-(3-methylbut-2-enyl)-6a,12a-dihydro-6H-[1]benzopyrano[3,4-b][1]benzopyran-12-one
amorphigeninAmorphigenin
deguelinA rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.deguelin
Dehydrodeguelin,7a,13a-DidehydrodeguelinDehydrodeguelin,7a,13a-Didehydrodeguelin
rotenoneA member of the class of rotenones that consists of 1,2,12,12a-tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one substituted at position 2 by a prop-1-en-2-yl group and at positions 8 and 9 by methoxy groups (the 2R,6aS,12aS-isomer). A non-systemic insecticide, it is the principal insecticidal constituent of derris (the dried rhizome and root of Derris elliptica).rotenone
tephrosinA member of the class of rotenones that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted with geminal methyl groups at position 3, hydroxy group at position 7a and methoxy groups at positions 9 and 10 (the 7aR,13aR stereoisomer). It is isolated from the leaves and twigs of Antheroporum pierrei and exhibits antineoplastic and pesticidal activities.tephrosin

Research

Studies (4,293)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-19901,174 (27.35)18.7374
1990's414 (9.64)18.2507
2000's930 (21.66)29.6817
2010's1,267 (29.51)24.3611
2020's508 (11.83)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials6 (0.13%)5.53%
Reviews94 (2.03%)6.00%
Case Studies13 (0.28%)4.05%
Observational0 (0.00%)0.25%
Other4,525 (97.56%)84.16%